{"brief_title": "Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)", "brief_summary": "The purpose of this trial is to study the safety and immune response to measles, mumps, and rubella in children who were vaccinated with an investigational measles-mumps-rubella live vaccine made with artificially made human protein.", "detailed_description": "The duration of treatment is 6 weeks.", "condition": "Varicella", "intervention_type": "Biological", "intervention_name": "Comparator: Measles, Mumps, and Rubella Virus Vaccine Live", "other_name": "V205C", "criteria": "Inclusion Criteria: - Healthy children 12 to 18 months of age Exclusion Criteria: - History or prior exposure to measles, mumps, or rubella - History of allergic reactions to any component of the vaccines as evaluated by the study doctor", "gender": "All", "minimum_age": "12 Months", "maximum_age": "18 Months", "healthy_volunteers": "Accepts Healthy Volunteers", "id": "NCT00092404.xml"}